1. Pink Sheet
  3. >>North America
  4. >>United States

Bayer Establishes Workspace For Start-Ups In An Innovative Move

 
• By Lisa LaMotta

One year after opening its Innovation Center in Mission Bay, Calif., Bayer is opening the space to start-ups to help establish their research labs.

Bayer AG is expanding efforts to reach out to community scientists in the U.S. with the formation of an incubator at its Mission Bay, Calif. innovation center. The initiative, announced Jan. 9, is intended to help start-ups get off the ground while also opening the door for research collaborations between Bayer scientists and researchers from biotech and academia.

Bayer has dubbed the project “CoLaborator” and plans to open research space to three or four start-up biotechs in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

BIO Notebook: MFN Pricing, Obesity R&D, US FDA’s Rare Disease Hub And Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.